Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 301 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo nasal aerosol Clear all
Recruiting Phase 4 Interventional

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304
View directory record Official record
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 4 Interventional

Study Of Patients With Allergic Rhinitis And Asthma

NCT00296530
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, montelukast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
80
States / cities
Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

NCT02742532
View directory record Official record
Conditions
Alcohol Use Disorder, Stress Disorders, Post-Traumatic, Anxiety Disorders, Substance Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 10, 2026, 6:58 AM EDT
Recruiting Phase 2 Interventional

Oxytocin for Weight Loss in Adolescents

NCT04551482
View directory record Official record
Conditions
Obesity, Adolescent, Oxytocin
Interventions
Oxytocin nasal spray, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

NCT01578278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 10, 2026, 6:58 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

NCT05045508
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray
Drug
Lead sponsor
Brandon Baartman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Early Phase 1 Interventional

Oxytocin and Cognitive Control in Adult ADHD

NCT03136263
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 1 Interventional

Cocaine Opioid Oxytocin Option - Limited

NCT02028533
View directory record Official record
Conditions
Opioid Use Disorder, Cocaine Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 3 Interventional Results available

Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

NCT04620369
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Nasal Vestibulitis
Interventions
Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 10, 2026, 6:58 AM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

NCT06358651
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 1 Interventional

Alcohol and Cigarette Craving During Oxytocin Treatment

NCT04071119
View directory record Official record
Conditions
Alcohol Use Disorder, Smoking
Interventions
Oxytocin nasal spray, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

NCT01307319
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, SAR
Interventions
BDP HFA, Placebo nasal aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 10, 2026, 6:58 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

PH94B in the Treatment of Adjustment Disorder With Anxiety

NCT04404192
View directory record Official record
Conditions
Adjustment Disorder With Anxious Mood
Interventions
PH94B, Placebo
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Watertown, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 10, 2026, 6:58 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients

NCT02147132
View directory record Official record
Conditions
Cigarette Smoking, Methadone Maintenance
Interventions
Nicotine Nasal Spray, Varenicline, Placebo Nasal Spray, Placebo Varenicline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

NCT01920893
View directory record Official record
Conditions
Nasal Polyps
Interventions
Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

NCT01807234
View directory record Official record
Conditions
Migraines
Interventions
Ketorolac, Sumatriptan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

NCT01832402
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Pectin Nasal Spray, Placebo Nasal Spray, Walk Test, Questionnaires, Mental Ability Tests
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Sinusitis

NCT00377403
View directory record Official record
Conditions
Acute Respiratory Infections, Acute Rhinosinusitis
Interventions
Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity

NCT03119610
View directory record Official record
Conditions
Obesity, Sarcopenic Obesity, Sarcopenia, Aging, Sedentary Lifestyle
Interventions
Oxytocin nasal spray, Placebo nasal spray
Drug
Lead sponsor
Sara Espinoza
Other
Eligibility
60 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 10, 2026, 6:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 10, 2026, 6:58 AM EDT